Option Care Health, a leading provider of home infusion services, has experienced a notable decline in its stock value, dropping approximately 40% since January 2026. This downturn is largely attributed to the expiration of Stelara's patent and subsequent shifts in insurance coverage policies, which have adversely affected the company's revenue streams and overall gross profit margins. Despite these headwinds, the company has managed to uphold its financial outlook for fiscal year 2026, maintaining its non-GAAP Earnings Per Share and Adjusted EBITDA guidance. This resilience is a result of proactive cost reduction strategies and other internal corporate initiatives aimed at mitigating the financial impact of external challenges. While the acute care portfolio has demonstrated robust performance, broader market share erosion and questions regarding the company's long-term credibility have contributed to the stock's current trading at 15 times its fiscal year 2026 estimated earnings per share. However, with favorable demographic trends, a solid financial foundation, and recent insider stock purchases, the current market undervaluation could present a strategic entry point for investors, particularly through cautious covered call options for tactical positions.

Option Care Health Faces Market Volatility Amidst Patent Expiry and Strategic Adjustments

In a significant market development for the healthcare sector, Option Care Health, a prominent entity in the home infusion services domain, has witnessed a substantial depreciation in its stock value. As of early 2026, the company's shares have plummeted by approximately 40%. This sharp decline is primarily linked to two critical factors: the expiration of the patent for Stelara, a key pharmaceutical product, and a series of adverse changes in insurance coverage policies. These events have collectively led to a reduction in market share for Option Care Health, directly impacting its revenue and gross profit. Specifically, the patent loss of Stelara alone has inflicted an estimated $125 million blow to the company's gross profit. This financial setback necessitated a downward adjustment of the fiscal year 2026 revenue guidance. However, in a display of strategic agility, Option Care Health has reaffirmed its non-GAAP Earnings Per Share (EPS) and Adjusted EBITDA guidance for the same period. This steadfastness is underpinned by rigorous cost-saving measures and various internal corporate actions designed to offset the revenue shortfalls. While the company's acute care segment has notably outperformed, concerns regarding sustained market share losses and a perceived dent in management's credibility have kept investor sentiment subdued, contributing to the stock trading at a relatively conservative valuation of 15 times its projected fiscal year 2026 EPS. Nevertheless, analysts point to several mitigating factors, including robust demographic tailwinds favoring home healthcare, a healthy balance sheet, and recent insider buying activities, suggesting that the current market sell-off might offer a strategic, albeit tactical, entry opportunity for investors willing to engage in covered call strategies.

The recent market performance of Option Care Health serves as a compelling case study on how external market dynamics, such as patent expirations and evolving insurance landscapes, can profoundly influence a company's valuation. It underscores the critical importance of a robust internal strategy, including aggressive cost management and strategic corporate actions, to navigate and mitigate such challenges. For investors, this scenario highlights the need for a nuanced understanding of both intrinsic company value and broader market sentiment. While the immediate outlook may appear challenging, the underlying fundamentals of Option Care Health, coupled with positive demographic trends and insider confidence, suggest a potential for recovery. This situation also emphasizes that even in times of market uncertainty, disciplined tactical investment approaches, such as covered calls, can offer pathways for engaging with high-quality assets during periods of undervaluation.